• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Verastem, Inc. - Common Stock (NQ:VSTM)

9.450 +0.220 (+2.38%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,798,268
Open 9.220
Bid (Size) 9.100 (50)
Ask (Size) 9.500 (22)
Prev. Close 9.230
Today's Range 9.100 - 9.470
52wk Range 3.455 - 11.24
Shares Outstanding 44,784,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Verastem Stock Ignites Retail Buzz After Early Cancer Drug Data Show Tumor Reduction, Mild Side Effects
October 24, 2025
Via Stocktwits
Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors
October 23, 2025
From Verastem Oncology
Via Business Wire

Performance

YTD
+45.6%
+45.6%
1 Month
+7.4%
+7.4%
3 Month
+55.4%
+55.4%
6 Month
+27.2%
+27.2%
1 Year
+151.3%
+151.3%

More News

Read More
Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025
October 23, 2025
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
October 19, 2025
From Verastem Oncology
Via Business Wire
Earnings Scheduled For August 7, 2025
August 07, 2025
Via Benzinga
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 07, 2025
From Verastem Oncology
Via Business Wire
Verastem Oncology to Present at Upcoming Investor Conferences
August 27, 2025
From Verastem Oncology
Via Business Wire
12 Health Care Stocks Moving In Wednesday's After-Market Session
August 13, 2025
Via Benzinga
Curious about the stocks that are showing activity after the closing bell on Wednesday?
August 13, 2025
Via Chartmill
Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics’ Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer
August 13, 2025
From Verastem Oncology
Via Business Wire
Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates
August 07, 2025
From Verastem Oncology
Via Business Wire
Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025
July 29, 2025
From Verastem Oncology
Via Business Wire
Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer
July 24, 2025
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
July 11, 2025
From Verastem Oncology
Via Business Wire
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
July 08, 2025
Via FinancialNewsMedia
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 08, 2025
From Verastem Oncology
Via Business Wire
Global Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
July 08, 2025
From FN Media Group LLC
Via GlobeNewswire
Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer
June 30, 2025
From Verastem Oncology
Via Business Wire
Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors
June 24, 2025
From Verastem Oncology
Via Business Wire
Verastem Announces Positive Data From Cancer Trial Conducted By Partner: Retail Turns Bullish
June 02, 2025
Via Stocktwits
12 Health Care Stocks Moving In Monday's Intraday Session
June 02, 2025
Via Benzinga
Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May
June 02, 2025
Via Benzinga
What's Going On With Verastem Oncology Stock On Monday?
June 02, 2025
Via Benzinga
Which stocks are experiencing notable movement on Monday?
June 02, 2025
Via Chartmill
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
June 02, 2025
From Verastem Oncology
Via Business Wire

Frequently Asked Questions

Is Verastem, Inc. - Common Stock publicly traded?
Yes, Verastem, Inc. - Common Stock is publicly traded.
What exchange does Verastem, Inc. - Common Stock trade on?
Verastem, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Verastem, Inc. - Common Stock?
The ticker symbol for Verastem, Inc. - Common Stock is VSTM on the Nasdaq Stock Market
What is the current price of Verastem, Inc. - Common Stock?
The current price of Verastem, Inc. - Common Stock is 9.450
When was Verastem, Inc. - Common Stock last traded?
The last trade of Verastem, Inc. - Common Stock was at 10/31/25 04:00 PM ET
What is the market capitalization of Verastem, Inc. - Common Stock?
The market capitalization of Verastem, Inc. - Common Stock is 423.21M
How many shares of Verastem, Inc. - Common Stock are outstanding?
Verastem, Inc. - Common Stock has 423M shares outstanding.
FinancialContent
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap